Acrux secures $5.4M Australian Lenzetto deal

Speciality pharmaceutical group Acrux (ASX:ACR) finalised an amendment to its licensing agreement with long-time partner Gedeon Richter for the transdermal estradiol spray, Lenzetto.

The revised agreement is poised to secure Acrux up to $5.4 million in upfront, regulatory, and commercial milestone payments within two years of the product’s Australian launch.

While specific terms remain commercial-in-confidence, the deal marks a critical commercial milestone for the Melbourne-based company.

The impending entry of Lenzetto into the domestic market is expected to alleviate a severe, ongoing shortage of menopause hormone therapy products across Australia.

As an advanced hormone replacement therapy, the spray treats symptoms associated with oestrogen deficiency in postmenopausal women, including severe hot flushes.

Lenzetto is an original Acrux development that already boasts a robust global footprint. It is currently licensed to and marketed by Gedeon Richter in more than 40 countries worldwide, generating substantial international sales that topped €50 million in 2025 alone.

At the time of reporting, Acrux’s share price was $0.016.